» Articles » PMID: 27028324

Unsupervised Analysis Reveals Two Molecular Subgroups of Serous Ovarian Cancer with Distinct Gene Expression Profiles and Survival

Abstract

Purpose: Ovarian cancer is typically diagnosed at late stages, and thus, patients' prognosis is poor. Improvement in treatment outcomes depends, at least partly, on better understanding of ovarian cancer biology and finding new molecular markers and therapeutic targets.

Methods: An unsupervised method of data analysis, singular value decomposition, was applied to analyze microarray data from 101 ovarian cancer samples; then, selected genes were validated by quantitative PCR.

Results: We found that the major factor influencing gene expression in ovarian cancer was tumor histological type. The next major source of variability was traced to a set of genes mainly associated with extracellular matrix, cell motility, adhesion, and immunological response. Hierarchical clustering based on the expression of these genes revealed two clusters of ovarian cancers with different molecular profiles and distinct overall survival (OS). Patients with higher expression of these genes had shorter OS than those with lower expression. The two clusters did not derive from high- versus low-grade serous carcinomas and were unrelated to histological (ovarian vs. fallopian) origin. Interestingly, there was considerable overlap between identified prognostic signature and a recently described invasion-associated signature related to stromal desmoplastic reaction. Several genes from this signature were validated by quantitative PCR; two of them-DSPG3 and LOX-were validated both in the initial and independent sets of samples and were significantly associated with OS and disease-free survival.

Conclusions: We distinguished two molecular subgroups of serous ovarian cancers characterized by distinct OS. Among differentially expressed genes, some may potentially be used as prognostic markers. In our opinion, unsupervised methods of microarray data analysis are more effective than supervised methods in identifying intrinsic, biologically sound sources of variability. Moreover, as histological type of the tumor is the greatest source of variability in ovarian cancer and may interfere with analyses of other features, it seems reasonable to use histologically homogeneous groups of tumors in microarray experiments.

Citing Articles

Multi-omics decipher the immune microenvironment and unveil therapeutic strategies for postoperative ovarian cancer patients.

Liu Z, Wang F, Chen W, Zhai Y, Jian J, Wang X Transl Cancer Res. 2024; 13(11):6028-6044.

PMID: 39697734 PMC: 11651737. DOI: 10.21037/tcr-24-656.


Comprehensive single-cell and bulk RNA-seq analyses reveal a novel CD8 T cell-associated prognostic signature in ovarian cancer.

Han Y, Fang Z, Gao Z, Li W, Yang J Aging (Albany NY). 2024; 16(12):10636-10656.

PMID: 38925650 PMC: 11236322. DOI: 10.18632/aging.205966.


A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.

Zhan F, Guo Y, He L J Ovarian Res. 2024; 17(1):92.

PMID: 38685095 PMC: 11057167. DOI: 10.1186/s13048-024-01419-y.


Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.

Sun W, Xu P, Gao K, Lian W, Sun X J Cell Mol Med. 2024; 28(8):e18309.

PMID: 38613345 PMC: 11015395. DOI: 10.1111/jcmm.18309.


HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.

Ma S, Wang J, Cui Z, Yang X, Cui X, Li X Sci Rep. 2024; 14(1):3870.

PMID: 38365849 PMC: 10873328. DOI: 10.1038/s41598-024-53854-y.


References
1.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

2.
Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C . Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clin Cancer Res. 2015; 21(13):2941-51. DOI: 10.1158/1078-0432.CCR-14-3111. View

3.
Karlan B, Dering J, Walsh C, Orsulic S, Lester J, Anderson L . POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2013; 132(2):334-42. DOI: 10.1016/j.ygyno.2013.12.021. View

4.
Fiszer-Kierzkowska A, Vydra N, Wysocka-Wycisk A, Kronekova Z, Jarzab M, Lisowska K . Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. BMC Mol Biol. 2011; 12:27. PMC: 3132718. DOI: 10.1186/1471-2199-12-27. View

5.
Wu Y, Chang T, Huang Y, Chen C, Chou C . COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 2015; 6(27):23748-63. PMC: 4695149. DOI: 10.18632/oncotarget.4250. View